Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: Methods and expectations  by Omer, Saad B. et al.
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Inﬂuenza  infection  in pregnancy  can  have  adverse  impacts  on maternal,  fetal,  and  infant  outcomes.
Inﬂuenza  vaccination  in pregnancy  is an appealing  strategy  to protect  pregnant  women  and  their  infants.
The  Bill &  Melinda  Gates  Foundation  is  supporting  three  large,  randomized  trials  in Nepal,  Mali,  and
South  Africa  evaluating  the  efﬁcacy  and  safety  of  maternal  immunization  to  prevent  inﬂuenza  disease  in
pregnant  women  and  their  infants  <6 months  of age.  Results  from  these  individual  studies  are  expected
in  2014  and  2015.  While  the  results  from  the  three  maternal  immunization  trials  are  likely  to  strengthen
the  evidence  base  regarding  the  impact  of  inﬂuenza  immunization  in pregnancy,  expectations  for  these
results  should  be realistic.  For  example,  evidence  from  previous  inﬂuenza  vaccine  studies  –  conducted
in  general,  non-pregnant  populations  – suggests  substantial  geographic  and  year-to-year  variability
in  inﬂuenza  incidence  and  vaccine  efﬁcacy/effectiveness.  Since  the evidence  generated  from  the  three
maternal  inﬂuenza  immunization  trials  will  be  complementary,  in  this  paper  we  present  a  side-by-side
description  of  the  three  studies  as  well  as the  similarities  and  differences  between  these  trials  in terms
of  study  location,  design,  outcome  evaluation,  and  laboratory  and  epidemiological  methods.  We also
describe  the likely  remaining  knowledge  gap  after  the  results  from  these  trials  become  available  along
with a description  of the analyses  that will  be conducted  when  the  results  from  these  individual  data  are
pooled.  Moreover,  we  highlight  that  additional  research  on  logistics  of seasonal  inﬂuenza  vaccine  supply,
surveillance  and  strain  matching,  and optimal  delivery  strategies  for  pregnant  women  will be  important
for  informing  global  policy  related  to  maternal  inﬂuenza  immunization.
ublis© 2015  The  Authors.  P
. IntroductionInﬂuenza infection in pregnancy can adversely impact mater-
al, fetal, and infant outcomes [1–7]. While pregnant women
end to be infected with the inﬂuenza virus at similar rates as
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non-pregnant women  of similar socio-demographic characteris-
tics, pregnancy increases their likelihood of adverse outcomes
after inﬂuenza infection. There are physiological changes in preg-
nancy such as decreased lung capacity, lower tidal volume,
and high cardiac output that could play a role in increas-
ing pregnant women’s vulnerability to adverse outcomes after
inﬂuenza infection [8,9]. More importantly, there are immunolog-
ical changes in pregnancy, such as Th1 to Th2 shift and attenuated
cell mediated immunity that modify a pregnant woman’s
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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bility to respond to certain infections—particularly viral infections
10,11].
The Bill & Melinda Gates Foundation (BMGF) is supporting
hree large, randomized trials evaluating the efﬁcacy and safety of
aternal immunization to prevent maternal and young–infant (<6
onths of age) inﬂuenza disease in Nepal, Mali, and South Africa
10]. The primary results from the South Africa trial have been
ublished [11] and results from the other two trials are expected
n 2014/2015 and will advance decisions on inﬂuenza vaccine
ntroduction for pregnant women in resource-limited settings. Fur-
hermore, a pooled analysis of data from these trials will be valuable
or understanding the beneﬁts of and building the evidence base for
his intervention, particularly for outcomes for which individual
rials may  not have been powered.
Since the evidence generated from these trials will be comple-
entary, in this paper we present a side-by-side description, as
ell as similarities and differences between these trials in terms
f study location, design, outcome evaluation, and laboratory and
pidemiological methods. We  discuss the expectations from these
rials and describe the outcomes selected for pooled analyses, the
rocess and criteria for selecting these analyses, and statistical
ethods to be used in the analyses. This will serve as a resource
or interpreting ﬁndings from the three BMGF-sponsored trials
s the results from these studies become available in the coming
ears.
. Rationale for conducting maternal inﬂuenza
mmunization trials
Inﬂuenza vaccination in pregnancy is an appealing strategy to
rotect pregnant women and their young–infants. There have been
everal recent developments in the ﬁeld of maternal inﬂuenza
mmunization. The World Health Organization’s Strategic Advisory
roup of Experts on Immunization has concluded that vaccination
f pregnant women is safe [12]. Furthermore, in a randomized con-
rolled trial in Bangladesh, administration of inactivated inﬂuenza
accine in the third trimester of pregnancy was associated with
eduction of conﬁrmed inﬂuenza (using rapid ELISA test) by 63%
mong infants younger than 6 months of age [13]. Maternal
nﬂuenza immunization has also been associated with protection
gainst adverse birth outcomes such as prematurity and small for
estational age birth in observational studies and post-hoc analyses
f trial data [3,14], although this ﬁnding has not been consistently
bserved by others [15] (particularly in studies that do not account
or inﬂuenza infection/circulation). Consequently, whereas these
dvances are promising, many questions remain.
While the Bangladesh trial was a signiﬁcant milestone for devel-
ping an evidence base for maternal inﬂuenza immunization, it
ad some limitations. For example, this trial was  conducted dur-
ng a single inﬂuenza season over an 11 month period. Since the
pidemiology of inﬂuenza varies substantially by geography and
eason, the ﬁndings from the Bangladesh trial need to be replicated
n other settings and over multiple seasons. Another limitation
f this trial is that the efﬁcacy of maternal inﬂuenza vaccination
as computed in comparison with the pneumococcal polysaccha-
ide vaccine (PPSV). While PPSV served as the comparison group
or the inﬂuenza vaccine analysis, PPSV was the main interven-
ion when the trial was initiated. PPSV could have affected the
isk of non-laboratory-conﬁrmed outcomes such as inﬂuenza-like
llness, which could have impacted on the true efﬁcacy of mater-
al inﬂuenza immunization against some outcomes. Moreover, the
ssociation between maternal inﬂuenza immunization and birth
utcomes was evaluated post hoc in the Bangladesh trial and has
ever been evaluated using a priori outcomes in a randomized con-
rolled trial. (2015) 3801–3812
3. Rationale for pooled analysis
We  sought to conduct a pooled analysis of data from the three
trials to further build an evidence base for maternal immuniza-
tion interventions. While the three trial sites will provide necessary
data as it relates to maternal immunization, by pooling the data, we
will be able to examine various outcomes for which individual tri-
als may  not have been powered. Pooled analysis, often described
as meta-analysis of individual level data, has several advantages
over “traditional” meta-analysis (i.e. meta-analysis based on sum-
mary estimates). In contrast with traditional meta-analysis, pooled
analysis allows for better standardization of analytical variables,
more robust confounder control, and greater ability to evaluate het-
erogeneity and effect modiﬁcation. Therefore, given that we have
access to individual level data from the three trials, we opted for the
pooled analysis approach rather than using the traditional group-
level meta-analysis to synthesize information from these trials.
4. Trial descriptions
A side-by-side description of the three trials is provided in
Tables 2–4 and supplement; a comparison of maternal mortality
ratios and infant mortality rates is also provided in Table 1. Brieﬂy,
all three are randomized, controlled, blinded trials. Enrollment
occurred from mid-September 2011 to mid-April 2013 in Mali, mid-
April 2011 to mid-April 2013 in Nepal, and March 2011 to August
2011 and March 2012 to July 2012 in South Africa. The enrollment
was targeted to coincide with the inﬂuenza season in South Africa;
whereas, the other two  sites enrolled and vaccinated participating
women year round. In Nepal, multiple peaks of inﬂuenza activ-
ity were observed in December 2011, August–October 2012, May
2013, June–August 2013, March–April 2014, July–September 2014,
and February–March 2015. In South Africa, the 2011 season had 2
distinct peaks. The ﬁrst peak, starting the week of 13 June which
was followed by a second peak, on the week of 26 September; 2012
season had a peak starting on the week of 20 August. In Mali, peaks
were observed in September/October and in February from 2010
to 2014.
In Mali, where there is no formal inﬂuenza vaccination policy,
pregnant women  receiving prenatal care at six referral centers and
community health centers in Bamako were offered enrollment. In
Nepal, where there is also no formal inﬂuenza vaccination policy,
women who were or who became pregnant in 9 Village Devel-
opment Committees in Sarlahi District in southern Nepal were
included; the participants were all identiﬁed by baseline house-
hold surveys. In South Africa, where there has been a national
campaign for inﬂuenza vaccination of pregnant women since
2010, enrollment was  conducted among women accessing pre-
natal care at Chris Hani-Baragwanath Hospital or at one of four
community-based antenatal clinics in Soweto region in Johan-
nesburg. Within the South African program, separate cohorts
of HIV-uninfected women  (n = 2108) and HIV-infected women
(n = 180) were enrolled. Only the HIV-uninfected cohort is included
in the proposed pooled analyses, as the primary objective of the
HIV-infected cohort was  evaluation of safety and immunogenicity
(rather than efﬁcacy) of inﬂuenza vaccine. Women  were enrolled
and vaccinated at ≥28 weeks of gestation in Mali, at 17–34 weeks
of gestation in Nepal, and at ≥20 to <36 weeks of gestation in South
Africa. Study subjects were followed from enrollment through
delivery and approximately 6 months of infant age at all three
sites (South Africa deﬁned the follow up period as 24 weeks post-
partum; whereas the other two sites deﬁned it as 6 months). Details
of differences in the eligibility criteria are described in Table 2.
Moreover, all three trials individually randomized the enrolled
women with a 1:1 randomization ratio using block randomization
S.B. Omer et al. / Vaccine 33 (2015) 3801–3812 3803
Table  1
Comparison of maternal mortality ratios and infant mortality rates across Mali, Nepal, and South Africa.
Trial site—morality rate and ratios
Mali Nepal South Africa
Maternal mortality ratio 540 per 100,000 live births (adjusted
for underreporting and
misclassiﬁcation). [460 per 100,000
live births reported.] [33]
280 per 100,000 live births (adjusted
for underreporting and
misclassiﬁcation). [170 per 100,000
live births reported.] [34]
400 per 100,000 live births (adjusted
for underreporting and
misclassiﬁcation). [300 per 100,000
live births reported.] [35]
Infant mortality rate 50 per 1000 births country-wide 27 per 1000 births country-wide
estim
19 per 1000 births country-wide
24 (
[37]
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iestimate [36]
42 (24–70) per 1000 live births (2012)
[37]
the block sizes varied between the trials). In all three trials, the
tudy subjects, investigators, and staff were blinded (except for
tatisticians, study pharmacists and, in case of Nepal and Mali, those
esponsible for vaccine administration). The vaccine brand, Vaxi-
rip (Sanoﬁ Pasteur) inactivated inﬂuenza vaccine was  the same
or all three trials. In Nepal and Mali, both Northern and Southern
emisphere versions of the vaccine were used for year round vacci-
ation; whereas, in South Africa, the Southern hemisphere version
f the vaccine was used. In Nepal and South Africa, the vaccine
ontained the following antigens: A/California/7/2009 (H1N1)-like,
/Perth/16/2009 (H3N2)-like, B/Brisbane/60/2008-like during both
ears. In Mali, the vaccine had the same antigens as the other
wo sites from September 2011 through November 2012; however,
rom December 2012 through April 2013, the vaccine contained
/California/7/2009 (H1N1)-like, A/Victoria/361/2011 (H3N2)-like,
/Wisconsin/1/2010-like antigens.
The Mali trial used Menactra (Sanoﬁ Pasteur), meningococcal
olysaccharide diphtheria toxoid conjugate vaccine (groups A, C,
, W-135) as the control vaccine. The Nepal and South Africa tri-
ls were placebo-controlled. In all trials, surveillance for maternal
nd infant outcomes was conducted through weekly home visits or
elephonic contacts, and nasopharyngeal specimens were obtained
rom subjects meeting the clinical case deﬁnition (Table 2), as well
s any unsolicited respiratory illness visit in South Africa. rRT-PCR
as used at all three sites for laboratory conﬁrmation of suspected
ases (Table 3). South Africa utilized a 2 step rRT-PCR for universal
etection of type A (subtypes H1 and H3) and B inﬂuenza viruses.
ali utilized a 1 step rRT-PCR to detect 2009 pandemic H1N1 and
easonal inﬂuenza viruses. Nepal utilized a 1 step rRT-PCR to detect
easonal inﬂuenza A (H1 and H3) and H1N1 subtypes.
In Mali, based on 90% power to detect 60% vaccine efﬁcacy
reduction from 2.2% to 0.88% attack rate), 77 cases of laboratory-
onﬁrmed inﬂuenza in infants were required to meet primary
bjectives. While the trial originally planned for 5440 enrollments
o achieve the 77 cases, this was not necessary as target laboratory-
onﬁrmed inﬂuenza was reached before then and enrollment was
topped with 4193 women vaccinated (one woman  was inad-
ertently vaccinated twice). In Nepal, the total target enrollment
as 3700 (i.e. 1850 in each of the 2 annual independently pow-
red cohorts). The sample size was based on 90% power to detect
0% vaccine efﬁcacy (reduction from 21.6 cases/100 person-years
f PCR conﬁrmed inﬂuenza illness in infants) in each of the two
nnual cohorts. In addition to inﬂuenza related outcomes, the Nepal
rial was powered for birth outcomes including low birth weight,
reterm birth, and small for gestational age. In South Africa, total
arget enrollment was 2108, based on 80% power to detect 50% vac-
ine efﬁcacy (reduction from 5% attack rate of conﬁrmed inﬂuenza
llness in infants).. Outcome selection process
The outcomes for the pooled analysis were outlined by a work-
ng data group composed of investigators from the three trial sites,ate [36] estimate [36]
18–32) per 1000 live births (2012) 15 (9–26) per 1000 live births (2012)
[37]
external experts, and BMGF personnel. Trial protocols, data dic-
tionaries, and case report forms (where available) were reviewed
to document similarities and differences among the three trials.
Speciﬁc trial aspects considered for outcome selection included
study design, inclusion and exclusion criteria, experimental and
comparator vaccines, data collection time points, and study time
periods. Outcome abstraction included only those outcomes related
to inﬂuenza.
For data abstraction, protocols were reviewed for stated pri-
mary, secondary, tertiary, and other outcomes. If speciﬁc outcomes
were not identiﬁed in trial protocols, case report forms and data
dictionaries were consulted to determine whether data on those
outcomes were collected. Outcome deﬁnitions were identiﬁed from
trial protocols, where available. In some cases, we  further speciﬁed
outcome deﬁnitions using data dictionaries or case report forms.
Where possible, speciﬁc case report forms used to capture out-
comes were identiﬁed and, where applicable, absence of data on
speciﬁc outcomes was  noted. We  then calculated available statis-
tical power for each outcome in pooled analyses (see Supplement)
and categorized potential outcomes according to available statisti-
cal power for within-site and pooled analyses, and the value added
by conducting pooled analyses. The categories were as follows:
Group A: Insufﬁcient power for analysis within individual trials,
but sufﬁcient power in pooled analyses; Group B: Sufﬁcient power
for analysis within individual trials, but potential for added ben-
eﬁt of pooled analyses across by evaluating geographic variability
and other site-speciﬁc factors, improving generalizability; Group C:
Sufﬁcient power for analysis within individual trials, limited poten-
tial for gain in efﬁciency through pooled analyses. The outcomes
identiﬁed through this process, along with relevant categories, are
presented in Supplement.
Through this process, 52 outcomes were identiﬁed for pooled
analyses: 21 in category A, 17 in category B, and 14 in category C. We
expect to group these outcomes into 11–13 analyses/manuscripts.
The list of expected analyses is described in Box 1.
6. Power and pooled cohort size
We determined an assumed baseline rate or prevalence for each
pooled outcome across the three trial sites based on three sources
of information. First, we consulted trial protocols from the Mali,
Nepal, and South Africa sites, as well as data available from the
Mother’s Gift trial in Bangladesh. Second, we searched PubMed for
relevant literature with data on the pooled outcomes in Mali, Nepal,
and South Africa, as well as summary estimates in nearby countries
across Africa and Asia, or across developing countries. Third, we
consulted reports from sources including the World Health Organi-
zation, March of Dimes, United Nations Children’s Fund (UNICEF),
United Nations Population Fund (UNFPA), and the Nepal Depart-
ment of Health Services. A complete list of sources consulted is
provided in the Supplement.
For binary and rate outcomes, we hypothesized that inﬂuenza
vaccine would reduce the prevalence or rate of each outcome
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Table 2
Comparison of study designs across maternal inﬂuenza immunization trials in Mali, Nepal, and South Africa.
Trial site—study design and methods
Mali Nepal South Africa
Design Randomized, controlled,
observer-blind trial
Randomized, placebo controlled,
community-based trial
Randomized, double-blind,
placebo-controlled trial
Study
population
Pregnant women receiving
prenatal care at six referral centers
and community health centers in
Bamako. The community health
centers are staffed by trained
midwives while the referral
centers have an obstetrician on
staff
Women  who are or who become
pregnant in 9 Village Development
Committees in Sarlahi District, Nepal.
The healthcare centers within the
Village Development Committees are
staffed by traditional birth attendants
HIV-uninfected women accessing prenatal
care at Chris Hani-Baragwanath Hospital or
at  one of four community-based antenatal
clinics in Soweto region. The
community-based clinics are staffed by
midwives; in addition, women identiﬁed
as having complicated or high-risk
pregnancies would be assessed by medical
doctors, including obstetricians at the
hospital
Stated primary
objectives
To compare the incidence of
laboratory-conﬁrmed inﬂuenza
(LCI) among infants up to 6 months
of age born to mothers immunized
with trivalent inﬂuenza vaccine
(TIV) during the 3rd trimester of
pregnancy versus infants born to
mothers who  received
meningococcal conjugate vaccine
(MCV) during the 3rd trimester of
pregnancy (intention-to-treat (ITT)
comparison)
To compare the incidence of LCI
among infants up to 6 months of
age born to mothers immunized
with TIV during the 3rd trimester
of pregnancy versus infants born to
mothers who  received MCV  during
the 3rd trimester of pregnancy, for
infants born to women  immunized
≥14 days prior to delivery
To compare the incidence of laboratory
conﬁrmed inﬂuenza illness episodes
among newborn infants (through 6
months of age) born to women
randomized to receive either inﬂuenza
vaccine or control during pregnancy
To compare the incidence of low
birthweight (<2500 g) of newborn
infants born to women randomized to
receive either inﬂuenza vaccine or
control during pregnancy
To compare the incidence of
inﬂuenza-like illness (ILI) episodes
among pregnant women  (through 6
months postpartum) in women
randomized to receive either inﬂuenza
vaccine or control during pregnancy
To determine the efﬁcacy of TIV
vaccination of pregnant women against
laboratory-conﬁrmed inﬂuenza illness, due
to  wild-type inﬂuenza strains which are
homologous to vaccine-strains, in their
infants up to 24 weeks of chronological age
To evaluate the immunogenicity of TIV in
pregnant women vaccinated between
20–36 weeks of gestational age
Enrollment Third trimester of pregnancy (28
weeks or later)
17–34 weeks of gestation ≥20 to <36 weeks of gestation
Follow-up Enrollment to infant 6 months of
age
Enrollment to infant 6 months of age Enrollment to infant 24 weeks of age
Major  maternal
eligibility
criteria
In third trimester of pregnancy,
intends to reside within study area
until her newborn infant is 6
months of age
Lives within one of 9 selected VDCs;
between 17 and 34 weeks gestation
≥18 to <39 years of age; gestational age
20–<36 weeks, HIV-1 uninfected
Major maternal
exclusion
criteria
History of severe inﬂuenza vaccine
reaction, Guillain-Barre syndrome,
egg allergy, chronic medical
condition; known active infection
with HIV, hepatitis B, or hepatitis
C; complications with ongoing
pregnancy (preterm labor,
placental abruption, rupture of
membranes, known major
congenital anomaly,
preeclampsia); acute illness or
high temperature within 72 h of
vaccination [temporary exclusion
criterion]; receipt of any other
vaccine excluding tetanus toxoid
within 2 weeks (inactivated
vaccines) or 4 weeks (live vaccines
and meningococcal A conjugate
vaccine); intends to travel out of
study area in the 40 days after
delivery; receipt of
immunoglobulins or any blood
products within 30 days of study
vaccine; chronic usage of
immunosuppressants or other
immune-modifying agents within
90 days of study vaccine
Does not intend to deliver child within
9 VDCs in study area; already received
current inﬂuenza vaccine; allergic to
any component of vaccine; >34 weeks
gestation. Also, excluded from primary
analyses if delivers <2 weeks following
receipt of study vaccine
Receipt of TIV (other than through the
study) during current inﬂuenza season
documented by medical history/record;
receipt of any live licensed vaccine in last
28 days or inactivated licensed vaccine
(except for TT) in last 14 days prior to
study vaccine; receipt of non-licensed
agent (e.g., vaccine, drug) in last 28 days
before vaccination or plans to receive such
before delivery; any signiﬁcant acute
illness and/or oral temperature (≥38 ◦C) in
last 24 h prior to study entry [temporary
exclusion criterion]; use of anti-cancer
systemic chemotherapy or radiation in last
48 weeks before study enrollment or has
immunosuppression as a result of
underlying illness or treatment; long-term
use of glucorticoids or high-dose inhaled
steroids within 12 weeks of study entry;
receipt of corticosteroids for preterm labor
within 14 days before study entry; receipt
of  immunoglobulin or other blood
products within 12 weeks before
enrollment or is scheduled to receive such
during pregnancy or for ﬁrst 24 weeks
after delivery; receipt of IL-2, IFN, GMCSF
or other immune mediators within 12
weeks before enrollment; uncontrolled
major psychiatric disorder; history of
severe adverse reaction to previous TIV;
pregnancy complications in current
pregnancy (e.g., preterm labor,
hypertension)
S.B. Omer et al. / Vaccine 33 (2015) 3801–3812 3805
Table  2 (Continued)
Trial site—study design and methods
Mali Nepal South Africa
Randomization 1:1 randomization at each health
center, using blocks of size
divisible by 2
1:1 randomization, blocked by VDC
(Cohort 1) or by VDC and gestational
age at vaccination [17–24 weeks,
25–34 weeks] because timing of
vaccination not randomly/uniformly
distributed (Cohort 2)
1:1 randomization, in blocks of 30 by
enrollment site
Blinding Observer-blinded (subjects and
those involved in clinical
surveillance for inﬂuenza and
adverse reactions blinded),
vaccination nurses not blinded
Only vaccinator will be un-blinded
(will not be involved in assessment of
reactogenicity or illness)
The statistician was responsible for
generation of the randomization codes and
therefore, was not blinded; however, the
statistician was not involved in subject
enrollment, case ascertainment or any
Box 1: The list of expected pooled analyses.
• Estimating overall (pooled) efﬁcacy of maternal inﬂuenza
immunization against infant and maternal lab conﬁrmed inﬂuenza.
This analysis may also focus on determinants of variability in vaccine
efﬁcacy by site, season, and vaccine composition
•  Impact of maternal inﬂuenza immunization on birth outcomes such as
pre-term and small for gestational age births
•  Immunogenicity of maternal TIV by site and antigen, dynamics of
mother to infant antibody transfer. This analysis may also focus on
determinants of variability in vaccine immunogenicity by site,
vaccine composition, and maternal and infant characteristics
•  Analysis of safety outcomes in mothers and infants—with a particular
focus on endpoints too rare to be evaluated in individual trials (e.g.,
miscarriage, stillbirth)
•  Impact of maternal TIV on neonatal mortality—all cause and, where
possible, cause speciﬁc mortality
• Impact of maternal TIV on maternal mortality
•  Infant growth by maternal vaccination status
• Indirect/”herd” effects of maternal TIV. Inﬂuenza-like illness and
laboratory conﬁrmed inﬂuenza among household contacts (Mali and
Nepal only)
• Impact of maternal TIV on infant Pneumonia
•  Impact of maternal TIV on (a) Medically Attended Acute Respiratory
Illness (MAARI) among mothers and infants, and (b) Severe acute
respiratory infection (mothers only). The working group might decide
b
d
b
i
p
t
b
y
U
s
a
e
2
t
t
a
c
5
7
ato  recommend separate analyses for mothers and infants
y 10–50%. Therefore, it was assumed that the difference to be
etected was an Odds Ratio of 0.5 to 0.9 (by 0.05 increments) for
inary outcomes and an Incidence Rate Ratio of 0.5 to 0.9 (by 0.05
ncrements) for rate outcomes. For continuous outcomes and pro-
ortions, we assumed a difference between means or proportions
o be detected between the inﬂuenza vaccine and control groups
ased on available data on baseline prevalence. NCSS Power Anal-
sis & Sample Size (PASS) software versions 11 and 12 (Kaysville,
T) was used for power calculations.
For pooled outcomes that will be analyzed across all three trial
ites, a sample size of 8500 to 11,500 (by 500 increments) was
ssumed. This sample size is based on the sum of the total target
nrollments across the three trials (5440 in Mali; 3700 in Nepal;
116 in South Africa), accounting for up to approximately 25% loss
o follow up. For certain outcomes, data are only available from
wo of the three trial sites; therefore, the assumed sample size was
djusted accordingly. In addition, within-site power for certain out-
omes was computed, assuming a sample size of 1500 to 4000 (by
00 increments) based on the sizes of the three trials.. Analytical approaches for pooled analyses
Our overall goal is to conduct methodologically appropriate
nalyses to generate results that could be communicated to a rangeother component of the study. All
remaining staff in the data management
team was blinded
of stakeholders including researchers, policy makers, clinicians, and
public health practitioners. This pooled analyses is designed to be
conducted after the end of enrollment and follow up at each site.
Our analytical approach was informed by this goal. We  anticipate
our primary analyses to use ﬁxed effects model with evaluation of
an interaction term for site. If signiﬁcant interaction is found, then
this term will be included in the ﬁnal model. In order to account
for heterogeneity among the three sites, we may  use a cluster term
for trial site to generate robust conﬁdence intervals. Where appro-
priate, we  will conduct sensitivity analyses using random effects
model, with random intercept for site. This will treat variability
across sites as a nuisance parameter, and will give a single estimate
for the effect of vaccine on each outcome. In some cases, we will
consider evaluating random slope for the effect of vaccine by site.
8. Expectations from and interpretations of trial results
While the results from the BMGF-sponsored maternal immu-
nization trials are likely to strengthen the evidence base regarding
the impact of inﬂuenza immunization in pregnancy, expecta-
tions from these results should be realistic. For example, evidence
from previous inﬂuenza vaccine studies – conducted in general,
non-pregnant populations – suggests substantial geographic and
year-to-year variability in inﬂuenza incidence and severity, as well
as vaccine efﬁcacy/effectiveness. In this section, we discuss a few
sources of heterogeneity and the role of underlying effect mod-
iﬁers that could impact ﬁndings (and their interpretations) from
the maternal inﬂuenza immunization trials.
8.1. Variations in inﬂuenza epidemiology
There is known seasonal variation in inﬂuenza disease patterns.
In a systematic review of seasonal inﬂuenza epidemiology in sub-
Saharan Africa [16], studies of seasonality reported over at least 12
consecutive months showed strong seasonality in Zambia, Mada-
gascar, and South Africa (southern Africa) and weak seasonality in
Senegal (closer to the equator). Another review of inﬂuenza surveil-
lance data from 85 countries between 1983 and 2008 compared the
timing of seasonal epidemic inﬂuenza activity in tropical, subtrop-
ical, and temperate regions [17]. The majority of countries had one
annual inﬂuenza epidemic (often comprising of multiple viruses)
rather than having multiple epidemics per year: 85% (40/47) of tem-
perate countries (i.e. countries with latitude >30◦), 100% (6/6) of
subtropical countries (i.e. latitude 23.6–29◦), and 56% (18/32) of
tropical countries (i.e. latitude ≤23.5◦). Countries with year-round
inﬂuenza activity (n = 15) were more likely to be located in the
tropics, speciﬁcally in Southeast Asia. Across all countries included
in the review, the mean duration of inﬂuenza epidemics was  4
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Table 3
Comparison of surveillance and diagnostic assays across maternal inﬂuenza immunization trials in Mali, Nepal, and South Africa.
Trial site—surveillance and diagnostic assays
Mali Nepal South Africa
Maternal study
vaccine
Vaxigrip (Sanoﬁ Pasteur), inactivated trivalent
inﬂuenza vaccine. Southern hemisphere versions.
From 09/2011 to 11/2012, A/California/7/2009
(H1N1)-like, A/Perth/16/2009 (H3N2)-like,
B/Brisbane/60/2008-like. From 12/2012 to 04/2013,
A/California/7/2009 (H1N1)-like, A/Victoria/361/2011
(H3N2)-like, B/Wisconsin/1/2010-like
Vaxigrip (Sanoﬁ Pasteur), inactivated trivalent
inﬂuenza vaccine. Southern and Northern hemisphere
versions, containing A/California/7/2009 (H1N1)-like,
A/Perth/16/2009 (H3N2)-like, B/Brisbane/60/2008
Vaxigrip (Sanoﬁ Pasteur), inactivated trivalent
inﬂuenza vaccine. Southern hemisphere version,
containing A/California/7/2009 (H1N1)-like,
A/Perth/16/2009 (H3N2)-like, B/Brisbane/60/2008
Control  Menactra (Sanoﬁ Pasteur), meningococcal
polysaccharide diphtheria toxoid conjugate vaccine
(groups A, C, Y, W-135)
Placebo (saline injection) Placebo (saline injection)
Timing of vaccine
administration
Third trimester of pregnancy (28 weeks or later) 17–34 weeks gestation ≥20 to <36 weeks gestation
Maternal inﬂuenza
surveillance
Weekly visits Weekly home visits Weekly visits
Infant  inﬂuenza
surveillance
Weekly visits Weekly home visits Weekly visits
Clinical deﬁnition
of inﬂuenza in
mother
Laboratory-conﬁrmed inﬂuenza: positive
nasopharyngeal swab specimen for inﬂuenza (PCR
testing)
Inﬂuenza-like illness:
Case of febrile inﬂuenza-like illness in mothers
according to study case deﬁnition as follows:
If  observed by the examining physician or part of
clinical history:
−Onset of fever (oral temperature ≥ 38 ◦C) < 7 days
duration AND
−Cough or sore throat AND
−Absence of other diagnoses
OR
−Onset of feverish feeling <7 days duration AND
−Cough or sore throat or chest pain on breathing in
AND
−Absence of other diagnoses
OR
−Sudden onset of fever over 38 ◦C or perception of
fever and self-administration of antipyretic in the
previous 8 h AND
−Cough or sore throat AND
−Shortness of breath or difﬁculty breathing
−Patient may  or may not be hospitalized. NB: This is
the deﬁnition of severe acute respiratory infection
Laboratory-conﬁrmed inﬂuenza:
An episode of respiratory illness (reported or
measured fever (>38 ◦C) plus one or more of the
following: cough, sore throat, runny nose, nasal
congestion, or myalgia) plus a positive laboratory test
for inﬂuenza from nasal swab(s)
Episodes must be separated by 7 or more days
Inﬂuenza-like illness:
CDC deﬁnition of ILI, requires reported or measured
fever (>38 ◦C) plus either cough or sore throat on one
or more days
Episodes of ILI must be separated by 7 or more days
Laboratory-conﬁrmed inﬂuenza:
Positive rRTPCR test for inﬂuenza virus
Case of laboratory-conﬁrmed inﬂuenza in mother
deﬁned as: Adult participant with
laboratory-conﬁrmed inﬂuenza (PCR from NP/OP swab
positive for inﬂuenza A or B)
Inﬂuenza-like illness:
Case of inﬂuenza-like illness in mother according to
study case deﬁnition as follows:
−Fever (≥38 ◦C on oral measurements) or chills/rigor
or  feeling feverish in past 7 days AND
−Cough/sore throat/pharyngitis OR
−Muscle, joint, or headache OR
−Feeling short of breath, had difﬁculty breathing or
chest pain while breathing AND
−Absence of other diagnoses
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Clinical deﬁnition
of inﬂuenza in
infant
Laboratory-conﬁrmed inﬂuenza:
Positive nasopharyngeal swab specimen for inﬂuenza
(PCR testing)
Inﬂuenza-like illness:
Case of febrile inﬂuenza-like illness in infants
according to study case deﬁnitions as follows
0–5-month-olds: Either of the 2 following conditions
reported by caretaker or observed by clinician: (1)
Fever w/o  apparent source, documented by clinician’s
measurement to be an axillary temperature > = 38 ◦C or
maternal perception of fever and administration of
antipyretic in previous 8 h (no source means there is
no apparent cause for the fever such as soft tissue
infection, although generalized symptoms such as
irritability, loss of appetite, and/or lethargy may  be
present;
OR (2) Fever (as deﬁned below)* plus acute respiratory
infection. Acute respiratory infection is deﬁned as ANY
of the following on the same or consecutive days:
runny nose, nasal congestion, cough, difﬁculty
breathing, pus draining from ear or wheezing;
PLUS >7 days after last reported fever
6–59-month olds: Either of the following conditions
reported by caretaker or observed by clinician: (1)
Fever w/o  apparent source, documented by a
clinician’s measurement to be an axillary temperature
≥38 ◦C or maternal perception of fever and
administration of antipyretic in previous 8 h (No
source means that there is no apparent cause for the
fever such as soft tissue infection, although
generalized symptoms such as irritability, loss of
appetite, and/or lethargy may be present;
OR (2) Fever (as deﬁned below)* plus acute respiratory
infection (acute respiratory infection deﬁned as ANY of
the  following on the same or consecutive days: runny
nose, nasal congestion, cough, difﬁculty breathing,
wheezing, sore throat, headache, earache, muscle
ache); PLUS
>7 days after last reported fever
Deﬁnition of fever: Any of the following – (1) Mother’s
perception that child had a fever during the previous
24 h; (2) Mother measured the child’s temperature as
>38 ◦C during the previous 24 h; (3) Clinician or study
staff measure the child’s temperature to be >38 ◦C; (4)
Maternal perception of fever and administration of
antipyretic in previous 8 h
Laboratory-conﬁrmed inﬂuenza:
An episode of respiratory illness (one or more of the
following: reported or measured fever (>38 ◦C), cough,
runny nose, wheeze, difﬁcult or rapid breathing,
draining ear) plus a positive laboratory test for
inﬂuenza from nasal swab
Episodes must be separated by 7 or more days
Inﬂuenza-like illness:
Modiﬁed CDC deﬁnition of inﬂuenza-like illness,
including reported or measured fever (>38 ◦C) plus
cough, or runny nose, or draining ear, or nasal
congestion occurring on one or more days
Episodes of ILI must be separated by 7 or more days
Laboratory-conﬁrmed inﬂuenza:
Positive rRTPCR test for inﬂuenza virus
Case of laboratory-conﬁrmed inﬂuenza deﬁned
according to study case deﬁnition as follows: Infant
with laboratory-conﬁrmed inﬂuenza (PCR from nasal
sample positive for inﬂuenza A or B) and at least one of
the following: fever, cough, runny nose, wheezing,
difﬁculty breathing, tachypnea
Inﬂuenza-like illness:
Case deﬁned according to study protocol case
deﬁnition, as follows
Fever (≥37.8 ◦C axillary temperature) of acute onset
(<7 days) without an apparent source, as documented
by parent/caregiver/study staff (no source means that
there is no apparent cause for the fever, such as soft
tissue infection, although generalized symptoms such
as  irritability, loss of appetite, and/or lethargy may  be
present); OR Fever (documented as ≥37.8 ◦C and/or
mother’s perception that infant is feverish/hot) plus at
least one sign/symptom of acute respiratory infection
within the past 72 h; OR At least 2 signs/symptoms of
ARTI within the past 72 h:
−Tachypnea (RR≥60 breaths/min in infant 0-2 months
of  age; RR≥50 breaths/min in infant 2-12 months of
age);
−Difﬁculty breathing (reported by mother:
noisy/interrupted/irregular/or fast)
−Coughing
−Wheezing
−Runny or congested nose
−Cyanosis/O2 saturation <90% (if available)
−Chest wall indrawing
−Grunting on expiration
−Pus draining from ear
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Table 3 (Continued)
Trial site—surveillance and diagnostic assays
Mali Nepal South Africa
Maternal
nasopharyngeal
swab collection
&  testing
If inﬂuenza-like symptoms present at weekly visit
Possible PCR test results are inﬂuenza A/human H1,
A/human H3, B, pandemic H1N1 (swine inﬂuenza),
H5a or H5b (avian inﬂuenza). 25% sample of specimens
that are positive for inﬂuenza A viruses of swine H1N1,
“human” H1N1 or H3N2 type, or inﬂuenza B viruses,
will  be antigenically characterized
If inﬂuenza-like symptoms present at weekly visit
Specimens tested using PCR for inﬂuenza A. Specimens
testing positive for inﬂuenza A will be subtyped for
seasonal inﬂuenza A H1 and H3 subtypes and the novel
H1N1 (swine origin) subtype using real time one-step
RT-PCR assays
If inﬂuenza-like symptoms present at weekly visit
If  presenting with unsolicited respiratory illness,
irrespective of fulﬁlling ILI criteria
Specimens tested using PCR. Specimens testing
positive for inﬂuenza A will be subtyped as H1 or H3
subtypes. All inﬂuenza-positive samples also
sequenced to determine “vaccine match” to vaccine
strains for H1 and H3
Infant
nasopharyngeal
swab  collection
If inﬂuenza-like symptoms present at weekly visit
Possible PCR test results are inﬂuenza A/human H1,
A/human H3, B, pandemic H1N1 (swine inﬂuenza),
H5a or H5b (avian inﬂuenza). 25% sample of specimens
that are positive for inﬂuenza A viruses of swine H1N1,
“human” H1N1 or H3N2 type, or inﬂuenza B viruses,
will  be antigenically characterized
Note: In Mali, nasal and throat swabs were collected
If inﬂuenza-like symptoms present at weekly visit
Specimens tested using PCR. Specimens testing
positive for inﬂuenza A will be subtyped for seasonal
inﬂuenza A H1 and H3 subtypes and the novel H1N1
(swine origin) subtype using real time one-step
RT-PCR assays
If inﬂuenza-like symptoms present at weekly visit
If  presenting with unsolicited respiratory illness,
irrespective of fulﬁlling ILI criteria
Specimens tested using PCR. Specimens testing
positive for inﬂuenza A will be subtyped as H1 or H3
subtypes. All inﬂuenza-positive samples also
sequenced to determine “vaccine match” to vaccine
strains for H1 and H3
Maternal serum
collection
Vaccine delivery, 1 month post-vaccination, delivery, 3
months post-delivery, 6 months post-delivery
Enrollment, delivery Enrollment, 1 month post-vaccination (28-35 days),
delivery (within 1 week of birth) and at 24 weeks
post-partum[only in immunogenicity sub-cohort]
Infant  serum
collection
Delivery (cord blood if delivered at study health
center; if not, peripheral blood collected before day 7
after birth), 3 months of age, 6 months of age
Delivery (cord blood) Delivery (within 1 week of birth), 8 weeks of age, 16
weeks of age, and 24 weeks of age [only in
immunogenicity sub-cohort]
Infant  specimen
collection for
other pathogens
Nasal and throat swabs taken when infants meet
criteria for inﬂuenza-like illness, and from 1/3 of
healthy infants at 3 and 6 months of age
Viral and pertussis assays performed on nasal swabs NP swabs for S. pneumoniae and S. aureus at 8 weeks of
age, 16 weeks of age, 24 weeks of age, and during
weekly visits if respiratory illness
Maternal  specimen
collection for
other pathogens
Nasal and throat swabs taken when mothers meet
criteria for inﬂuenza-like illness
Viral and pertussis assays performed on nasal swabs NP and OP swabs for S. pneumoniae colonization at
weekly visits if suspected of pneumonia
Planned  sample
size
Total target enrollment was 5440, based on 90% power
to detect 60% vaccine efﬁcacy (reduction from 2.2% to
0.88% attack rate), with 5% type 1 error rate, accounting
for  20% loss to follow-up due to death, withdrawal, and
exclusion of mothers receiving vaccine <14 days prior
to delivery from primary analysis
Required 77 cases of laboratory-conﬁrmed inﬂuenza in
infants to meet primary objectives. While originally
planned for 5440, this was not necessary as target
laboratory-conﬁrmed inﬂuenza was  reached before
then
Total target enrollment was  1850 in each of 2 cohorts,
based on 90% power to detect 50% vaccine efﬁcacy
(reduction from 21.6 cases/100 person-years), with
1.7% type 1 error rate, accounting for 6 months
follow-up per infant, stillbirth/miscarriage, and loss to
follow up
Total target enrollment was  2116, based on 80% power
to  detect 50% vaccine efﬁcacy (reduction from 5%
attack rate), with 5% type 1 error rate, accounting for
10% loss to follow up
Target number of cases of laboratory-conﬁrmed
inﬂuenza illnesses due to wild-type inﬂuenza virus
(homologous to vaccine strain) was  27, to detect 70%
reduction in laboratory-conﬁrmed inﬂuenza illness in
infants, based on 80% power and 80% of infants being
born during the inﬂuenza season.
Assumed baseline
incidence of
laboratory-
conﬁrmed
inﬂuenza among
infants in study
area
2.2% attack rate for laboratory-conﬁrmed inﬂuenza in
infants (counting only ﬁrst cases of inﬂuenza)
21.6 cases of proven inﬂuenza illness/100 person-years
among infants 0–6 months of age
5% attack rate in infants
Dates  of
enrollment
9/12/2011 to 4/19/2013 Cohort 1: mid-April 2011 to mid-April 2012
Cohort 2: mid-April 2012 to mid-April 2013
Started 3 March 2011 and ended 4 Aug 2012 for 1st
cohort and 2nd cohort enrolled from 6 March 2012 to
2  July 2012
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Table  4
Comparison of Outcomes across Maternal Inﬂuenza Immunization Trials in Mali, Nepal, and South Africa.
Trial site—outcomes
Mali Nepal South Africa
Primary Inﬂuenza infection: Laboratory-conﬁrmed inﬂuenza
(infant)
Birth outcomes: Low
birthweight Inﬂuenza infection
Inﬂuenza-like illness (mother)
Laboratory-conﬁrmed
inﬂuenza (infants)
Immunogenicity: Seroprotection
Inﬂuenza infection:
Laboratory-conﬁrmed inﬂuenza
(infant)
Secondary Birth outcomes:
Congenital malformations
Low birthweight
Other birth complications
Preterm birth
Hospitalization: Hospitalizations for
laboratory-conﬁrmed inﬂuenza (infant)
Immunogenicity:
Geometric mean titer for infant
Maternal/fetal HAI titer ratio (infant)
Cell-mediated immune response to each inﬂuenza
strain (mother)
Geometric mean titer (mother)
Regulatory B cell subpopulation (mother)
Regulatory T cell subpopulation (mother)
T-cell activation (mother)
Seroprotection, by absolute titer for infant
Inﬂuenza antibody in breast milk
Inﬂuenza infection:
Inﬂuenza-like illness in infants
Inﬂuenza-like illness (mother)
Laboratory-conﬁrmed inﬂuenza (mother)
Laboratory-conﬁrmed inﬂuenza illness due to all
wild-type strains, irrespective of match to vaccine
strain (mother)
Laboratory-conﬁrmed inﬂuenza illness due to
wild-type inﬂuenza strains, irrespective of match to
vaccine strain (infant)
Laboratory-conﬁrmed inﬂuenza illness due to
wild-type inﬂuenza strains that are heterologous to
vaccine strains (infant)
Laboratory-conﬁrmed inﬂuenza illness due to
wild-type inﬂuenza strains that are heterologous to
vaccine strains (mother)
Pneumonia: S. pneumoniae carriage fever (infants)
Other pathogens:
In infants
In mothers
Pregnancy complications:
Preeclampsia
Stillbirth
Gestational hypertension
Safety:
Any SAE (mother)
Any SAE (mother)
Fatigue (mother)
Fever (mother)
Headache (mother)
Malaise (mother)
Myalgia (mother)
Nausea (mother)
Rash (mother)
Presence of redness at injection site (mother)
Swelling at injection site (mother)
Tenderness (mother)
Pain at injection site (mother)
Meningitis:
Geometric mean titer (mother)
Fatigue
Fever
Headache
Myalgia
Pain at injection site
Redness at injection site
Swelling at injection site
Serious adverse event
Birth outcomes:
Gestational age
Preterm birth
Small for gestational age
Hospitalization:
Hospitalizations for
laboratory-conﬁrmed
inﬂuenza (infant)
Hospitalizations (infant)
Hospitalizations (mother)
Inﬂuenza infection:
Inﬂuenza-like illness in
household contacts
Inﬂuenza-like illness in infants
Laboratory-conﬁrmed
inﬂuenza in household
contacts
Laboratory-conﬁrmed
inﬂuenza in mothers
Other pathogens:
Infant
Mother
Pregnancy complications:
Miscarriage
Stillbirth
Clinic visits:
Clinic visits for inﬂuenza-like
illness (infant)
Clinic visits for inﬂuenza-like
illness (mother)
Hepatitis:
Acute viral hepatitis
Anti-HEV IgG prevalence
Biochemical correlates of
clinical HEV disease, among
women who seroconvert
Disease to infection ratio for
HEV, among women who
seroconvert
HEV genotypes present in
incident cases
HEV infection (anti-HEV
seroconversion)
Risk factors for HEV
seroconversion
Infant outcomes: Infant growth
Infant outcomes: Neonatal
mortality
Maternal outcomes: Maternal
mortality
Birth outcomes:
Low birthweight
Preterm birth
Other birth complications
Hospitalization:
Hospitalizations for
laboratory-conﬁrmed inﬂuenza, in
infants
Hospitalizations, in infants
Immunogenicity:
Geometric mean titer (infant)
Maternal/fetal HAI titer ratio
(infant)
Cell-mediated immune response to
each inﬂuenza strain (mother)
Geometric mean titer (mother)
Regulatory B cell subpopulation
(mother)
Regulatory T cell subpopulation
(mother)
T-cell activation (mother)
Seroprotection, by absolute titer
(infant)
Inﬂuenza antibody in breast milk
Inﬂuenza infection:
Inﬂuenza-like illness in infants
Inﬂuenza-like illness in mothers
Laboratory-conﬁrmed inﬂuenza
illness due to all wild-type strains,
irrespective of match to vaccine
strain, in mothers
Laboratory-conﬁrmed inﬂuenza
illness due to wild-type inﬂuenza
strains, irrespective of match to
vaccine strain, in infants
Laboratory-conﬁrmed inﬂuenza
illness due to wild-type inﬂuenza
strains that are heterologous to
vaccine strains, in infants
Laboratory-conﬁrmed inﬂuenza
illness due to wild-type inﬂuenza
strains that are heterologous to
vaccine strains, in mothers
Laboratory-conﬁrmed inﬂuenza in
mothers
Pneumonia: S. pneumoniae
carriage (infant)
Other pathogens:
Infant
Mother
Safety:
Any SAE in infant
Any SAE in mother
Fever (mother)
Headache (mother)
Malaise (mother)
Myalgia (mother)
Nausea (mother)
Rash (mother)
Presence of redness at injection
site (mother)
Swelling at injection site (mother)
Tenderness (mother)
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Table 4 (Continued)
Trial site—outcomes
Mali Nepal South Africa
Tertiary Birth outcomes: Birth weight
Cost:
Cost of inﬂuenza-like illness in infants up to 6 months
Cost of inﬂuenza-like illness in pregnant women  up to
6  months post-partum
Cost of laboratory-conﬁrmed inﬂuenza in infants up to
6  months
Cost of laboratory-conﬁrmed inﬂuenza in pregnant
women up to 6 months post-partum
Immunogenicity:
Geometric mean titer (infants)
Maternal/fetal HAI titer ratio (infants)
Inﬂuenza infection:
Asymptomatic infection with inﬂuenza virus in
healthy infants at 3 and 6 months of age
Laboratory-conﬁrmed inﬂuenza in household contacts
Inﬂuenza virus circulation: Inﬂuenza virus types
circulating in the study population
Meningitis:
Geometric mean titer (infants)
Meningococcal disease in infants
Serogroup-speciﬁc serum bactericidal antibodies (A, C,
Y,  and W-135) in pregnant women
Other pathogens (infant)
Severe acute respiratory infection (mother)
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inﬂuenza seasons, when match was  poor, VE was −10% (95% CI:
−36–40) and 21% (95% CI: −52–59), respectively. In the 2006–2007onths, and peak inﬂuenza activity was modestly associated with
ower temperature.
There are several potential reasons for heterogeneity in
nﬂuenza epidemiology. Tamerius et al. reviewed evidence for the
ollowing potential seasonal mechanisms explaining seasonal pat-
erns of inﬂuenza disease activity: seasonal variations in (1) host
ontact rate, (2) virus survival, and (3) host immunity [18].
It has been hypothesized that frequency of contacts between
nfected and susceptible hosts is seasonally patterned (e.g.,
ncreased frequency of contact due to indoor crowding in colder
onths) [19]. Contact rates may  be inﬂuenced by school sched-
les, temperature, travel and workﬂow patterns, and precipitation
e.g., colder weather in temperate regions, rainy weather in tropical
egions). However, some studies have found contradictory results,
uch as winter inﬂuenza epidemics in desert regions of the U.S.
here there is likely higher crowding during hot summer months.
herefore, the authors concluded that there is a lack of strong
mpirical data to support this contact hypothesis, and that this
echanism likely operates in combination with other causes of
easonal variation in inﬂuenza [18].
Moreover, seasonal variation in inﬂuenza disease patterns could
e due to differences in virus survival, in response to temperature,
elative humidity, absolute humidity, and exposure to ultraviolet
adiation (e.g., sun exposure) [18]. Lower absolute humidity tends
o be associated with higher virus survival among guinea pigs;
owever, the occurrence of tropical inﬂuenza epidemics during the
ainy season cannot be explained by this effect [18]. Higher virus
urvival may  be associated with less exposure to ultraviolet radi-
tion; this hypothesis could explain inﬂuenza epidemics in both
emperate regions (winter) and tropical regions (rainy season) [20].
There may  also be seasonal variations in hosts’ general immu-
ity to inﬂuenza, which make them less likely to develop
nﬂuenza-like symptoms during non-epidemic months [18]. This
ay  be inﬂuenced by temperature and humidity, exposure to
unlight and vitamin D levels, nutrient availability, changes in air-
orne particulate matter and pollutants, higher energy required for
hermoregulation during winter or rainy seasons, and interaction
etween inﬂuenza virus and other pathogens [18].8.2. Variability in vaccine efﬁcacy/effectiveness
Osterholm et al. conducted a systematic review and meta-
analysis of randomized controlled trials and observational studies
of inactivated inﬂuenza vaccine [21]. In this analysis, including 8
randomized controlled trials of trivalent inactivated vaccine (TIV)
conducted in 31,892 adults aged 18–64 years over 9 inﬂuenza
seasons, 5 trials found a signiﬁcant protective effect of TIV. The
random-effects pooled vaccine efﬁcacy was  59% (95% CI: 51–67).
The vaccine efﬁcacy among healthy adults ranged from 16% to 75%
with substantial variability from season to season and between
studies [21]. Moreover, in one randomized controlled trial of TIV
in children aged 6–24 months conducted over two  inﬂuenza sea-
sons, vaccine efﬁcacy was  66% in the ﬁrst season (1999–2000) and
−7% in the second season (2000–2001). Both seasons had a good
match between vaccine and circulating strains. Nine observational
studies of seasonal inﬂuenza vaccine effectiveness comprising of
17 seasonal or separate cohort analyses were eligible for inclu-
sion in this review. Among the 17 analyses, 6 (35%) reported a
signiﬁcant protective effect of seasonal inﬂuenza vaccine against
medically attended, laboratory-conﬁrmed inﬂuenza with substan-
tial variability between seasons.
8.3. Effects of vaccine match
Antigenic mismatch between vaccine and circulating strain
affects vaccine effectiveness. For example, among healthy 18–64
year olds in the U.S., vaccine effectiveness for the poor match
1997–1998 inﬂuenza season was 50% (not signiﬁcantly protective).
In comparison, vaccine effectiveness for the good match 1998–1999
inﬂuenza season was 80% (signiﬁcantly protective) [22]. Among
children 6–23 months old and adults ≥65 years old in Wiscon-
sin, vaccine effectiveness varied across three inﬂuenza seasons
with differing antigenic match. In the 2004–2005 and 2005–2006inﬂuenza season, when match was  good, VE was 52% (95% CI:
22–70) [23]. Moreover, in a systematic review and meta-analysis
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y DiazGranados, Denis, and Plotkin [24]; randomized or quasi-
andomized controlled trials were eligible for inclusion. Overall
accine efﬁcacy of inactivated vaccines (any type/subtype) was
6% (95% CI: 48–63) for any strain/season, 66% (95% CI: 49–77) for
atched strains, 55% (95% CI: 42–65) for not matched strains, 54%
95% CI: 42–64) for good match season; and 49% (95% CI: 28–64)
or poor match season.
.4. Underlying effect modiﬁers
An additional aspect of maternal inﬂuenza immunization is the
otential for a protective effect of inﬂuenza vaccine in pregnancy
n neonatal outcomes such as preterm, small for gestational age
irths, and low birth weight [3,14]. Since these birth outcomes
ave a multifaceted etiology, the variability in underlying rates of
ovariates such as maternal nutritional status, obesity, and baseline
aternal antibody titer due to previous infection and/or vaccina-
ion can inﬂuence the efﬁcacy of maternal inﬂuenza vaccination
gainst birth outcomes.
Moreover, trans-placental transfer of maternal antibodies is
n important mechanism for infant protection against inﬂuenza.
other-to-infant IgG transfer has been shown to be inﬂuenced by
aternal co-infection. For example, among women who received
ntenatal tetanus toxoid, malaria infection during pregnancy has
een associated with reduced infant antibody levels [25,26].
etanus antibody titers were 48% lower among neonates of women
ith documented placental malaria when compared with neonates
orn without evidence of placental malaria infection [25]. However,
ndings of an impact of malaria infection on antibody transfer have
ot been consistent. For example, studies in Malawi and The Gam-
ia found no association between placental malaria and tetanus
ntibody levels in the newborn [27]. It could be that the differ-
ng results for the impact of malaria infection on antibody transfer
elate to variations in prevalence of severe malaria.
Similarly, maternal HIV infection has been observed to have
ariable effect on efﬁciency of transplacental IgG transfer, differ-
ng for antibody to different epitopes [28]. However, in general
IV-infected mothers had lower antibody levels, albeit similar
fﬁciency of transfer in terms of geometric mean ratios (GMRs)
or trans-placental transfer [28–30]. There are few studies on the
mpact of HIV infection on transfer of maternal inﬂuenza anti-
ody. A recent trial of 2009 pH1N1 inﬂuenza immunization during
regnancy among HIV-infected pregnant women showed 65% with
ero-protective HAI titers (≥1:40) among infants at birth, which
aned to 26% at 3 months and 12% at 6 months [31].
While there are data on the impact of malaria and HIV on mater-
al antibody transfer, these data do not include inﬂuenza antibody
ransfer. Given the possibility of maternal co-infection (e.g., with
IV and/or malaria) modifying transfer of inﬂuenza antibodies to
he infant, there is a need to characterize the inﬂuence of mater-
al co-infection on inﬂuenza antibody transfer, an issue which will
e addressed in the BMGF South African study involving an HIV-
nfected cohort. Moreover, there is a need for data on maternal
fﬁcacy of maternal inﬂuenza vaccine from locations with high HIV
nd/or malaria prevalence.
. Beyond the pooled analyses
In 2013, GAVI Alliance explored the possibility of fund-
ng seasonal inﬂuenza vaccination for pregnant women as part
f their Vaccine Investment Strategy (VIS) development pro-
ess. Inﬂuenza vaccine was not recommended for this round of
nvestments—primarily due to the “high degree of uncertainty
round the estimates of inﬂuenza vaccination impact” as there
as only been a single randomized controlled trial of maternal (2015) 3801–3812 3811
immunization in a low-income country [32]. However, this uncer-
tainty is likely to be resolved after the results from the three BMGF
funded trials become available. The VIS recommended that “the
[GAVI] Board may  want to consider preparatory activities to facil-
itate re-evaluation of inﬂuenza vaccine support in the next VIS
process. Such preparatory activities could focus on acquiring addi-
tional data on implementation feasibility and addressing questions
relating to the logistics of seasonal vaccine supply, surveillance
and strain matching, and optimal delivery strategies for pregnant
women.” [32]. Therefore, in order to facilitate decision making
regarding broad adoption of maternal inﬂuenza immunization in
developing countries, data beyond the three trials will be needed.
We will also encourage documenting lessons learned and best
practices from low and middle income countries with inﬂuenza
vaccination policies.
Speciﬁc examples of additional data gaps include logistics for
integrating maternal inﬂuenza immunization into antenatal care
delivery in low and middle income countries. While low and mid-
dle income countries have substantial experience in delivering
tetanus toxoid (or tetanus and diphtheria toxoid) in pregnancy,
moving from a single vaccine to a multiple dose schedule will
require consideration and assessment of supply chain logistics, bar-
riers to integration into the staff workﬂow, and understanding of
vaccine acceptance among pregnant women and their health care
providers. Moreover, selection of a vaccine product with a strain
composition relevant to countries with perennial inﬂuenza circu-
lation, and deciding whether some countries need both Northern
and Southern vaccine at different times of the year, will require
ongoing acquisition and synthesis of data on inﬂuenza circulation
in low and middle income countries.
There is need for additional data to determine the optimal
timing of inﬂuenza vaccination during pregnancy. For example,
depending on the effects of immunization on various outcomes,
it may  be more important to protect the woman  for longer during
the pregnancy than giving it later in pregnancy. However, the chal-
lenge is that many women in developing countries seek care late
in pregnancy and maternal outcomes of inﬂuenza are worse later
in pregnancy.
Moreover, studies so far – including the three BMGF supported
trials – have primarily focused on mild to moderately severe dis-
ease. Evaluating the impact on severe outcomes, such as pneumonia
and hospitalization, would yield information on the full beneﬁt of
maternal inﬂuenza immunization. Furthermore, there have been a
few cost effectiveness analyses of maternal inﬂuenza immuniza-
tion. For example, a cost effective analysis from Mali found that the
impact on birth outcomes such as birth weight would be the most
important driver of cost effectiveness (unpublished data). However,
as the data from the three trials (and additional observational data)
become available, the cost effectiveness models may  need to be
upgraded.
10. Conclusions
Maternal inﬂuenza immunization is a promising strategy to
reduce morbidity and mortality associated with inﬂuenza among
pregnant women  and young infants. The results from the three
BMGF-sponsored trials are likely to substantially increase the evi-
dence base for the impact of maternal inﬂuenza immunization.
BMGF Supported Maternal Inﬂuenza Immunization Trials
Investigators GroupOrdered by site and alphabetically.
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